CenterBook Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$18.9M |
| 2 |
Tidewater
TDW
|
+$13.3M |
| 3 |
Five Below
FIVE
|
+$11.5M |
| 4 |
Biogen
BIIB
|
+$11.5M |
| 5 |
CG Oncology
CGON
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$17.1M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$14.2M |
| 3 |
Xponential Fitness
XPOF
|
+$9.88M |
| 4 |
Starbucks
SBUX
|
+$9.14M |
| 5 |
First Solar
FSLR
|
+$8.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.7% |
| 2 | Healthcare | 14.22% |
| 3 | Consumer Discretionary | 14.1% |
| 4 | Industrials | 13.33% |
| 5 | Energy | 9.79% |
Similar funds
CenterBook Partners's Q2 2024 Portfolio in Review
As of Q2 2024, CenterBook Partners held 479 positions worth $1.61B, up 11% from $1.45B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
CenterBook Partners deployed $233M of net new capital in Q2 2024, opening 106 new positions and adding to 161 existing holdings. Its largest new stake was BioNTech: 206,234 shares worth $16.6M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 26% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $14.2M trimmed.
- CenterBook Partners's largest Q2 2024 buy was BioNTech: 206,234 shares worth $16.6M.
- CenterBook Partners added most to Tidewater in Q2 2024, an estimated $13.3M increase.
- CenterBook Partners's biggest Q2 2024 reduction was Alphabet (Google) Class A, cutting an estimated $14.2M.
- CenterBook Partners fully exited Illumina in Q2 2024, selling an estimated $17.1M.
- CenterBook Partners's ten largest holdings make up 11% of its $1.61B portfolio in Q2 2024.
- CenterBook Partners opened 106 new positions and closed 91 in Q2 2024.
- CenterBook Partners's portfolio value rose 11% quarter-over-quarter to $1.61B.
Based on CenterBook Partners's 13F filing for Q2 2024, filed 12 Aug 2024.